Tag Archives: AbbVie

Bioverativ(BIVV) To Be Acquired By Sanofi(SNY) At Huge 64% Premium

It was just one year ago when Biogen(BIIB) spun off hemophilia and blood disorder specialist Bioverativ(BIVV). With the stock trading in the 40s post-spin, we highlighted some disparate analyst opinions of the spin. The most bullish, Gabelli & Company, has a price target of $58 for Bioverativ stock.  This past Friday, Bioverativ stock closed at $64.11, above Gabelli’s… Read More »

After Swallowing Baxalta, Barron’s Sees 25% Upside For Shire

Just months after being spun off from Baxter International(BAX), Baxalta found itself the target of an intense pursuit by Shire Pharmaceuticals(SHPG). Baxalta resisted, but, ultimately agreed to a deal which closed earlier this year. Barron’s sees good things ahead for the combined company. In an article this weekend, the venerable publication points out that merely by achieving a… Read More »

AbbVie Initiated at Outperform By Raymond James

AbbVie(ABBV) surged out of the gate following its January 2013 spinoff from Abbott Laboratories(ABT). By December 2014, the stock price had doubled. Since then, however, the stock languished, continuing to trade below its December 2014 highs. Despite efforts to diversify, Humira, which is now off patent, accounts for 60% of revenue. Barron’s reports that Raymond James now thinks… Read More »

Abbott Labs Getting Ready To Make $25 Billion Bid For St. Jude Medical

Abbott Labs(ABT), which spun off AbbVie(ABBV) in one of the largest spinoffs in recent years, is preparing to make a $25 billion bid for St. Jude Medical(STJ) according to a report in the Financial Times. Abbott and St Jude, which is based in St Paul, Minnesota, already have a strong alliance in the field of cardiovascular devices, and… Read More »

Summer Of Spin: Forbes’ Antoine Gara Likes PayPal and Baxalta

Amidst this great Summer Of Spin, what are the best prospects? According to Forbes’ Antoine Gara, who has also noted the flurry of spinoffs: PayPal and Baxalta(BXLT). About PayPal: PayPal is a leader in online payments, with high margins and strong revenue growth. It could prove valuable to tech giants like Google, Apple, Microsoftand Facebook, who are all toying… Read More »

13F Time: Bill Ackman Sells Alexander & Baldwin, Nelson Peltz Sells Kraft and Mondelez, Dan Loeb Buys Abbott and AbbVie

13F season is always fun as it provides a rare (albeit delayed) glimpse into the thinking of large money managers and hedge funds. Of course, due to the significant time lag (~45 days), the exclusion of certain securities (shorts, derivatives etc.) and varying investment strategies and holding periods, the usefulness of such data is…questionable in many cases. Not… Read More »

Can’t Decide Which One To Own? Cramer Picks Abbott Over AbbVie

Amidst our exhaustive coverage of the Abbott (ABT)/AbbVie (ABBV) separation, there has been no consensus as to which company is the ‘better’ one to own. Some people like AbbVie’s higher dividend yield while others prefer Abbott’s growth prospects. Ahhh what is an uninformed investor to do? Luckily, the self-appointed people’s champion stockpicker, CNBC’s Jim Cramer, has weighed in… Read More »

More AbbVie Inanity On Seeking Alpha With A Dose Of Penny Stock Promotion

Set a million monkeys loose with Yahoo Finance and a word processor, and what do you get? The answer, it would appear, is Seeking Alpha, a content farm with no particular editorial standards.  We wrote last week about blatant, significant errors being covered up without acknowledgement.  This morning, we encountered another wastebasket-worthy piece on AbbVie(ABBV). Imagine writing about… Read More »

AbbVie CFO: Big Acquisiton Not Prudent

AbbVie(ABBV) is a behemoth of a company following its spinoff from Abbott Laboratories(ABT), but it is a one-legged giant. The chorus of concern around the companies prospects has centered on its extreme dependence on a single drug, Humira, which accounts for 50% of revenues and 70% of profits. There has been speculation that the firm would use its… Read More »

Seeking Alpha Silently Updates Flawed Article On AbbVie, Fails To Note Heavy Post-Publication Editing

We wrote yesterday about a flawed article on SeekingAlpha about AbbVie(ABBV) and Abbott Laboratories(ABT) which contained information which was extremely erroneous(off by over $15 billion), and built a thesis based on that false data. The article, which can be found here, has been edited extensively, but something is missing: there is no indication anywhere on the page that… Read More »

Bad Data Leads To Bad Conclusion In Seeking Alpha AbbVie/Abbott Analysis

AbbVie(ABBV) is one of the most massive spinoffs we’ve seen, so every piece of news or analysis is of interest to us. Hence it was with great interest that we noted that Seeking Alpha published “AbbVie’s Shares Are More Appealing Than Abbott’s Following The Spin-Off” this morning.  We were pleased to see author Robert Broens put a stake… Read More »

AbbVie Declares $.40 Dividend, Yield Stands At Over 4.6%

Not wasting any time, AbbVie(ABBV) declared a $.40 quarterly dividend on Friday, two days after its spin off from Abbott Laboratories(ABT).  At Friday’s closing price of $34.39, the stock yields 4.65%. The dividend will be paid on February 15, 2013 to shareholders as of the close of business on January 15, 2013. For former Abbott shareholders continuing to… Read More »

Abbott and AbbVie- Spinoff Complete, Companies Begin To Walk Their Own Paths

On Wednesday, Abbott Laboratories(ABT) completed its spinoff of AbbVie(ABBV), and the two firms began their new, independent lives. As is often the case, as their first acts, each company issued a press release noting the occasion. Abbott’s release was relatively brief, wished AbbVie well, and gave a short picture of the new Abbott, focusing on the company’s many… Read More »

AbbVie Spin From Abbott Complete Today – Discussion Thread

After long preparations, Humira manufacturer AbbVie(ABBV) has been spun off from former parent Abbott Laboratories(ABT). Abbott shareholders will wake up to find one share of AbbVie in their account for every share of Abbott that they own. We have covered the story, but not performed any deep analysis of either company. So let’s hear from you, readers. What… Read More »

Morningstar Worries About AbbVie’s Reliance On Humira

It’s a few weeks old now, but with AbbVie’s(ABBV) spin from Abbott Laboratories(ABT) complete, we thought it worthwhile to mention this piece from Morningstar on AbbVie’s prospects.  No doubt,  the new company has many things going for it. A strong balance sheet is one: Following the split from Abbott, AbbVie will carry approximately $16 billion in debt and… Read More »